LiveKidney Initiates Phase I/IIa Trial of Novel Cell Therapy LK-SC001 for Lupus Nephritis
LiveKidney has enrolled the first patient in a Phase I/IIa clinical trial evaluating LK-SC001, a subcutaneous UC-MSC therapy, for lupus nephritis and systemic lupus erythematosus at the Medical University of South Carolina.
Cannabidiol Shows Limited Impact on Quality of Life in HIV Patients with Controlled Viral Load
A randomized, double-blind, controlled trial assessed the impact of cannabidiol (CBD) on the health-related quality of life (HRQoL) in HIV patients with long-term viral suppression.
FDA Approves New Therapies for Hemophilia, Colorectal Cancer, and Cystic Fibrosis
The FDA approved Alhemo (concizumab) from Novo Nordisk for hemophilia A and B with inhibitors, offering a once-daily subcutaneous option.
Real-World Study Affirms Axicabtagene Ciloleucel's Efficacy in LBCL, Expanding Patient Eligibility
A real-world study of 1297 patients confirms the efficacy of axicabtagene ciloleucel (axi-cel) in relapsed/refractory large B-cell lymphoma (LBCL).
PharmaDrug's PD-001 (Cepharanthine) Shows Stability in Preparation for Phase 1 Viral Disease Trial
PharmaDrug's Sairiyo Therapeutics has completed a successful stability study of its patented PD-001, an enteric-coated formulation of cepharanthine.
Altimmune Achieves FDA Agreement on Phase 3 Program for Pemvidutide in Obesity Treatment
Altimmune has reached an agreement with the FDA on the design of its Phase 3 program for pemvidutide in treating obesity, marking a significant regulatory milestone.
Antibody-Drug Conjugates: A Review of Clinical Efficacy and Recent Advances
Gemtuzumab ozogamicin (GO), the first approved ADC, initially faced safety concerns but was later re-approved for CD33-positive AML treatment at a lower dose.
FDA's Drug Trials Snapshots Highlight Sex Disparities in Cardiovascular Drug Trials
FDA's Drug Trials Snapshots program reveals demographic data and subgroup analysis for newly approved drugs, enhancing transparency.
SetPoint Medical's Neuroimmune Modulation Platform Receives FDA IDE Approval for Relapsing-Remitting MS Trial
SetPoint Medical received FDA approval for an IDE to study its neuroimmune modulation platform in relapsing-remitting MS patients.
Remimazolam Plus Esketamine Offers Enhanced Hemodynamic Stability in Elderly Patients Undergoing Colonoscopy
A randomized controlled trial found that remimazolam combined with esketamine (RE) provides superior hemodynamic stability compared to propofol with esketamine (PE) in elderly patients undergoing colonoscopy.
Preoperative Betamethasone Reduces Postoperative Nausea and Vomiting in Total Knee Arthroplasty Patients
A randomized controlled trial demonstrated that preoperative betamethasone significantly reduces nausea severity in patients undergoing total knee arthroplasty (TKA).
Machine Learning Identifies Serological Predictors of COVID-19 Outcomes
A study of hospitalized and non-hospitalized COVID-19 patients used machine learning to identify key serological markers associated with disease severity.
Genomically Distinct Subclass of Head and Neck Cancer Identified
Researchers have identified a genomically distinct subclass of head and neck squamous cell carcinoma (HNSCC) characterized by specific copy number alterations (CNAs).
UIC Scientists Develop Safer Asparaginase Treatment for Pediatric Leukemia
University of Illinois Chicago researchers have engineered a novel form of asparaginase that maintains its anti-cancer efficacy while eliminating severe side effects common to current treatments. The redesigned enzyme, derived from guinea pig proteins, shows promise in treating acute lymphoblastic leukemia and potentially other cancers, with reduced toxicity and longer intervals between treatments.
Breakthrough in Xenotransplantation: Genetically Modified Porcine Heart Transplanted into Human
A groundbreaking medical procedure was conducted where a genetically modified porcine heart was successfully transplanted into a human patient, marking a significant milestone in xenotransplantation research. This event was facilitated by the collaborative efforts of the University of Maryland Medical System, United Therapeutics, Inc., and various other contributors, showcasing the potential of genetic engineering in overcoming organ transplant shortages.
Sleeping Pill Shows Potential in Reducing Alzheimer's Proteins
A small study led by researchers at Washington University School of Medicine in St. Louis found that an FDA-approved sleeping pill, suvorexant, reduced levels of key Alzheimer's proteins in healthy volunteers. This suggests a potential pathway for sleep medications to slow or stop the progression of Alzheimer's disease, though further research is necessary to confirm these findings.
Federal Circuit Revives UC's CRISPR Patent Claims, Orders Re-Evaluation of Gene-Editing Breakthrough
The Federal Circuit ruled that the Patent Trial and Appeal Board used flawed legal reasoning when evaluating the University of California's claims to CRISPR-Cas9 gene-editing technology in animal cells.
Acticor Biotech Repositions Glenzocimab for Myocardial Infarction Treatment
Acticor Biotech is focusing on myocardial infarction with glenzocimab, encouraged by expert feedback on its potential in STEMI treatment.
Neuralink Receives Health Canada Approval for Brain-Computer Interface Trial
Neuralink has received Health Canada approval to launch its first global trial, CAN-PRIME, evaluating its implantable brain-computer interface (BCI) device.
Major Milestone for UQ Spin-Out's Promising MND Drug
A new treatment for motor neurone disease (MND) developed by NuNerve, a company spun-out from The University of Queensland, has shown promising results in a Phase 1 clinical trial. The drug, NUN-004, was found to be safe and effective, offering hope for slowing disease progression and improving motor movement in patients.